These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 22201977)

  • 1. Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.
    de la Monte SM
    Front Biosci (Elite Ed); 2012 Jan; 4(4):1582-605. PubMed ID: 22201977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.
    de la Monte SM
    Curr Alzheimer Res; 2012 Jan; 9(1):35-66. PubMed ID: 22329651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.
    de la Monte SM
    Drugs; 2012 Jan; 72(1):49-66. PubMed ID: 22191795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain metabolic dysfunction at the core of Alzheimer's disease.
    de la Monte SM; Tong M
    Biochem Pharmacol; 2014 Apr; 88(4):548-59. PubMed ID: 24380887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?
    Steen E; Terry BM; Rivera EJ; Cannon JL; Neely TR; Tavares R; Xu XJ; Wands JR; de la Monte SM
    J Alzheimers Dis; 2005 Feb; 7(1):63-80. PubMed ID: 15750215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.
    Rivera EJ; Goldin A; Fulmer N; Tavares R; Wands JR; de la Monte SM
    J Alzheimers Dis; 2005 Dec; 8(3):247-68. PubMed ID: 16340083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology.
    Kamat PK; Kalani A; Rai S; Tota SK; Kumar A; Ahmad AS
    Mol Neurobiol; 2016 Sep; 53(7):4548-62. PubMed ID: 26298663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis.
    Bosco D; Fava A; Plastino M; Montalcini T; Pujia A
    J Cell Mol Med; 2011 Sep; 15(9):1807-21. PubMed ID: 21435176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review.
    de la Monte SM
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1954-60. PubMed ID: 25088942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathology, Risk Factors, and Oxidative Damage Related to Type 2 Diabetes-Mediated Alzheimer's Disease and the Rescuing Effects of the Potent Antioxidant Anthocyanin.
    Khan MS; Ikram M; Park TJ; Kim MO
    Oxid Med Cell Longev; 2021; 2021():4051207. PubMed ID: 33728019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications.
    Zemva J; Schubert M
    CNS Neurol Disord Drug Targets; 2014 Mar; 13(2):322-37. PubMed ID: 24059318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease.
    Kim B; Elzinga SE; Henn RE; McGinley LM; Feldman EL
    Neurobiol Dis; 2019 Dec; 132():104541. PubMed ID: 31349033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-β Clearance.
    Gontier G; George C; Chaker Z; Holzenberger M; Aïd S
    J Neurosci; 2015 Aug; 35(33):11500-13. PubMed ID: 26290229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease.
    de la Monte SM; Wands JR
    J Alzheimers Dis; 2005 Feb; 7(1):45-61. PubMed ID: 15750214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linking insulin with Alzheimer's disease: emergence as type III diabetes.
    Ahmed S; Mahmood Z; Zahid S
    Neurol Sci; 2015 Oct; 36(10):1763-9. PubMed ID: 26248483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extending Arms of Insulin Resistance from Diabetes to Alzheimer's Disease: Identification of Potential Therapeutic Targets.
    Gupta S; Singhal NK; Ganesh S; Sandhir R
    CNS Neurol Disord Drug Targets; 2019; 18(3):172-184. PubMed ID: 30430949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.
    de la Monte SM
    Drugs; 2017 Jan; 77(1):47-65. PubMed ID: 27988872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin signaling: An opportunistic target to minify the risk of Alzheimer's disease.
    Pardeshi R; Bolshette N; Gadhave K; Ahire A; Ahmed S; Cassano T; Gupta VB; Lahkar M
    Psychoneuroendocrinology; 2017 Sep; 83():159-171. PubMed ID: 28624654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.